Mizuho Securities Gives a Buy Rating to FibroGen


In a report released today, Difei Yang from Mizuho Securities assigned a Buy rating to FibroGen (NASDAQ: FGEN), with a price target of $61. The company’s shares closed yesterday at $53.90.

According to TipRanks.com, Yang is a 5-star analyst with an average return of 21.2% and a 53.2% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.

FibroGen has an analyst consensus of Moderate Buy, with a price target consensus of $61.

See today’s analyst top recommended stocks >>

Based on FibroGen’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $41.4 million. In comparison, last year the company had a GAAP net loss of $33.16 million.

Based on the recent corporate insider activity of 111 insiders, corporate insider sentiment is negative on the stock. Most recently, in April 2018, Pat Controneo, the SVP, Finance and CFO of FGEN bought 33,550 shares for a total of $97,295.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

FibroGen, Inc. engages in the discovery, development, and commercialization of therapeutics to treat unmet medical needs. It focuses on fibrosis and hypoxia-induced factor biology to generate programs targeting therapeutic areas. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts